Inventor

Naomi Hosogai

Inventor

Tokyo, JP

Overview

5→

Patents

2000–2020

Patent span

Human necessities

Primary field (CPC A)

Patents· 5 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

A61Pprimary

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations25%

A61KPreparations for medical, dental or toiletry purposes20%

C07DHeterocyclic compounds15%

C07KPeptides10%

C12NMicroorganisms or enzymes10%

C12PFermentation or enzyme-using processes to synthesise a desired chemical compound or composition or to separate optical isomers from a racemic mixture10%

G01NInvestigating or analysing materials by determining their chemical or physical properties10%

PatentTitleYear

10,710,988Piperazine derivative2020 10,517,966Anti-human MUC1 antibody Fab fragment2019 10,507,251Anti-human MUC1 antibody fab fragment2019 10,301,286Piperazine derivative2019 6,069,156'Indole derivatives as cGMP-PDE inhibitors'2000

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2000Patents assigned to FUJISAWA PHARMACEUTICAL CO (1)· patent assignee history

2000Based in Tsukuba, JP· patent location history

2019–2020Patents assigned to ASTELLAS PHARMA INC (4)· patent assignee history

2019–2020Based in Tokyo, JP· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ASTELLAS PHARMA INC	4	2019–2020
FUJISAWA PHARMACEUTICAL CO	1	2000

Locations

Location	Patents	Span
Tokyo, JP	4	2019–2020
Tsukuba, JP	1	2000